

Please amend claim 7 as follows:

C1 7. The method of claim ~~6~~ 3 wherein the vector is an adenoviral vector.

Please cancel claims 13, 14, 15, 16 and 17.

D1
C2 34. A method of ~~treating~~ killing a hepatocellular carcinoma cell in a mammalian
~~subject suffering therefrom by contacting said hepatocellular carcinoma cell with the~~
~~administration of a pharmaceutical formulation comprising a recombinant vector comprising a~~
nucleic acid segment encoding an interferon- α polypeptide, the nucleic acid segment being
operatively linked to a promoter specific for a tissue of interest, wherein the nucleic acid segment
encoding the interferon- α polypeptide lacks a secretion leader sequence.

Please cancel claim 35.

Please amend claim 36 as follows:

C3 36. The method of claim ~~35~~ 34 wherein the ~~mammalian subject is a human being and~~
the interferon- α polypeptide is human interferon- α 2b.

STATUS OF THE CLAIMS FOLLOWING AMENDMENT

Claims 1-4, 6-9, 13-17, and 19-39 were pending in the parent application application. By this Preliminary Amendment, claims 6, 13,-17 and 35 have been cancelled. Claims 1, 7, 34 and 36 have been amended. Claims 1-4, 7-9, 19-34 and 36-39 are pending in this application.

REMARKS

A. Co-Pendency of CPA with Parent Application:

The parent application (Serial No. 09/353,423) was subject to a final rejection dated August 2, 2001 (Paper No. 9) setting a shortened statutory time for response of 3 months extendable pursuant to the provisions of 37 C.F.R. 1.136(a). On February 1, 2002, Applicants filed a petition for a three month extension of time to respond to the final rejection issued in the parent application and the requisite fee pursuant to 37 C.F.R.1.17(a)(3) extending the date for